
MS-444
CAS No. 150045-18-4
MS-444( —— )
Catalog No. M33436 CAS No. 150045-18-4
MS-444 (BE-34776) is a smooth muscle myosin light chain kinase (MLCK) and HuR inhibitor with antitumor activity for triple-negative breast and colorectal cancer.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 948 | Get Quote |
![]() ![]() |
25MG | 1674 | Get Quote |
![]() ![]() |
50MG | 2190 | Get Quote |
![]() ![]() |
100MG | 2790 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMS-444
-
NoteResearch use only, not for human use.
-
Brief DescriptionMS-444 (BE-34776) is a smooth muscle myosin light chain kinase (MLCK) and HuR inhibitor with antitumor activity for triple-negative breast and colorectal cancer.
-
DescriptionMS-444 inhibits the activity of purified smooth muscle myosin light chain kinase (MLCK) with an IC50 value of 10 μM.
-
In VitroMS-444 is a small molecule RNA-binding protein HuR (ELAVL1) inhibitor. Colorectal cancer (CRC) cells that display HuR overexpression are treated with MS-444 (1-100 μM) for 48 hr with IC50s of 10.98±1.76 μM, 12.84±2.10 μM, 5.60±0.90 μM, 14.21±2.11 μM, and 10.98±1.24 μM for HCT116, HCA-7, RKO, HT-29, and SW480 cells, respectively. Growth inhibition is observed in all CRC lines with IC50 values ranging from 5.60 μM to 14.21 μM with observable effects seen at 10 μM MS-444. Contrasting effects are observed using non-transformed small intestinal (RIE-1 (IC50=40.70±3.53 μM)) and colonic (YAMC (IC50=28.16±3.23 μM)) epithelial cells. Both cell types display properties of normal intestinal epithelial cells and are proficient in 3′UTR AU-rich elements (ARE)-mRNA decay. Both non-transformed cell lines are ~3- to 4-fold less responsive to MS-444-mediated growth inhibition, with IC50 values of 40.70 μM and 28.16 μM (P<0.05).
-
In VivoTo test the effects of MS-444 on CRC cell growth in vivo, mice bearing HCT116 cell xenografts receive IP injections of MS-444 (25 mg/kg bw) or vehicle every 48 hr. Over the experiment course, mice do not display any adverse effects and maintained similar weights. Anti-tumor effects of MS-444 are observed with approximately 1.7-fold reduction in tumor size. Mice treated with MS-444 show a marked 2- to 3-fold decrease inmicrovessel density (MVD), indicating the anti-angiogenic potential of MS-444.
-
Synonyms——
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetMyosin
-
RecptorMyosin | Serine/threonin kinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number150045-18-4
-
Formula Weight230.22
-
Molecular FormulaC13H10O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (217.18 mM; Ultrasonic )1-Methyl-2-pyrrolidinone : 20 mg/mL (86.87 mM; Ultrasonic)
-
SMILESO=C1C=2C(O)=CC=C(O)C2CC3=COC(=C13)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Satoshi Nakanishi. et al. MS-444, a new inhibitor of myosin light chain kinase from Micromonosporasp.KY7123. The Journal Of Antibiotics. 1995,48(9):948-951.?
molnova catalog



related products
-
Mavacamten
Mavacamten (SAR-439152, MYK-461) is a small molecule that reduces contractility by decreasing the ATPase activity of the cardiac myosin heavy chain.
-
Danicamtiv
Danicamtiv is an inotropic agent and it also is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.
-
BHC
BHC (Myosin inhibitor BHC) is a small-molecule screen of skeletal muscle myosin inhibitor.